Larocent Capsule 100 mg contains Larotrectinib, a highly selective targeted anticancer agent used for the treatment of solid tumors that harbor neurotrophic tyrosine receptor kinase (NTRK) gene fusions. Larotrectinib represents a precision medicine approach, as its use is based on a specific genetic alteration rather than the tumor’s site of origin. Larocent is indicated for both adult and pediatric patients with advanced or metastatic cancers where surgical resection is not feasible and no satisfactory alternative treatments are available.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Targeted Cancer Therapy / TRK Inhibitor

Pharmacology

Larotrectinib is a selective inhibitor of tropomyosin receptor kinases (TRK) A, B, and C, which are encoded by the NTRK1, NTRK2, and NTRK3 genes. NTRK gene fusions result in constitutively active TRK proteins that drive oncogenic signaling, leading to uncontrolled cell proliferation and survival.

By binding to the ATP-binding site of TRK proteins, Larotrectinib inhibits downstream signaling pathways such as MAPK, PI3K/AKT, and PLC-γ, thereby suppressing tumor growth and promoting apoptosis. Its high selectivity minimizes off-target effects, contributing to a favorable safety profile.

Pharmacokinetic characteristics include:

• Absorption: Rapid oral absorption with peak plasma concentrations within 1 hour

• Bioavailability: High and not significantly affected by food

• Protein binding: Approximately 70%

• Metabolism: Primarily hepatic via CYP3A4

• Elimination half-life: Around 3 hours

• Excretion: Mainly through feces and urine

Indications

Larocent Capsule 100 mg is indicated for the treatment of:

• Adult and pediatric patients with solid tumors harboring an NTRK gene fusion

• Metastatic or locally advanced cancers where surgical resection would result in severe morbidity

• Tumors that have progressed following prior treatments or have no satisfactory alternative therapy

This includes, but is not limited to, certain lung cancers, thyroid cancers, soft tissue sarcomas, salivary gland tumors, and pediatric malignancies with confirmed NTRK gene fusion.

Dosage and Administration

• Adults: The recommended dose is 100 mg orally twice daily

• Pediatric Patients: Dose is based on body surface area as per clinical guidelines

• Capsules should be swallowed whole with water and may be taken with or without food

• Treatment should continue until disease progression or unacceptable toxicity occurs

Dose Adjustments:

• May be required in patients with moderate to severe hepatic impairment

• Temporary interruption or dose reduction may be necessary in case of adverse reactions

Contraindications

• Known hypersensitivity to Larotrectinib or any of its components

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Common adverse effects include:

• Fatigue and dizziness

• Nausea, vomiting, and diarrhea

• Constipation and abdominal discomfort

• Anemia and elevated liver enzymes

• Weight gain

Serious but less frequent side effects may include neurotoxicity, hepatotoxicity, and hypersensitivity reactions.

Precautions and Warnings

• Monitor liver function tests prior to and during treatment

• Use caution in patients with pre-existing neurological disorders

• Concomitant use with strong CYP3A4 inhibitors or inducers should be carefully managed

Pregnancy and Lactation

• Pregnancy Category D: May cause fetal harm; effective contraception is recommended during treatment

• Breastfeeding should be avoided during therapy and for a period after discontinuation

Storage Conditions

Store below 30°C, protected from light and moisture. Keep out of reach of children.

Mode of Action

Larocent Capsule 100 mg works by selectively inhibiting TRK fusion proteins, blocking oncogenic signaling pathways responsible for tumor growth and survival. This targeted mechanism enables effective tumor control across multiple cancer types with NTRK gene fusions.